Target Name: MCM6
NCBI ID: G4175
Other Name(s): MCG40308 | Mis5 | minichromosome maintenance deficient (mis5, S. pombe) 6 | minichromosome maintenance complex component 6 | Minichromosome maintenance protein 6 | Minichromosome maintenance complex component 6 | P105MCM | p105MCM | MCM6 minichromosome maintenance deficient 6 (MIS5 homolog, S. pombe) | MCM6_HUMAN | Minichromosome maintenance deficient (mis5, S. pombe) 6 | DNA replication licensing factor MCM6

MCM6: A Potential Drug Target for Diseases

MCM6 (Muramylated-C and flattenediolase 6) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a key enzyme in the metabolization of cell membrane phospholipids, which are an essential component of cell structure and function. MCM6 is also involved in the transport of lipids across cell membranes, as well as in the production of various signaling molecules.

Recent studies have identified MCM6 as a potential drug target for a variety of diseases, including cardiovascular disease, neurodegenerative diseases, and liver diseases. This is because MCM6 is involved in the regulation of cellular signaling pathways that are involved in the development and progression of these diseases.

One of the reasons why MCM6 is thought to be a promising drug target is because it is involved in the production of various signaling molecules that are involved in cell signaling pathways that are involved in the development and progression of many diseases. For example, MCM6 is involved in the production of various signaling molecules that are involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

MCM6 is also involved in the production of various signaling molecules that are involved in the regulation of cellular signaling pathways that are involved in the development and progression of cardiovascular disease. the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body.

Another reason why MCM6 is thought to be a promising drug target is because it is involved in the regulation of cellular signaling pathways that are involved in the development and progression of liver diseases. For example, MCM6 is involved in the production of various signaling molecules that are involved in the regulation of fibrosis, which is the process by which cells become abnormally organized and form tissue.

In addition to its involvement in cellular signaling pathways, MCM6 is also thought to be involved in the regulation of various cellular processes that are involved in the development and progression of diseases. For example, MCM6 is involved in the regulation of cellular processes that are involved in the production and degradation of various signaling molecules, as well as in the regulation of cellular processes that are involved in the production and degradation of various signaling molecules.

Overall, MCM6 is a protein that is involved in a variety of cellular processes that are involved in the development and progression of diseases. As a result, it is a potential drug target for a variety of diseases, including cardiovascular disease, neurodegenerative diseases, and liver diseases. Further research is needed to fully understand the role of MCM6 in these diseases and to develop effective treatments.

Protein Name: Minichromosome Maintenance Complex Component 6

Functions: Acts as component of the MCM2-7 complex (MCM complex) which is the replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. Core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built (PubMed:32453425, PubMed:34694004, PubMed:34700328, PubMed:35585232, PubMed:16899510, PubMed:9305914). The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity (PubMed:32453425)

More Common Targets

MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8